These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1119 related items for PubMed ID: 24246420

  • 1. CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study.
    Paajanen T, Hänninen T, Tunnard C, Hallikainen M, Mecocci P, Sobow T, Tsolaki M, Vellas B, Lovestone S, Soininen H.
    J Alzheimers Dis; 2014; 39(3):679-90. PubMed ID: 24246420
    [Abstract] [Full Text] [Related]

  • 2. CERAD neuropsychological battery total score in multinational mild cognitive impairment and control populations: the AddNeuroMed study.
    Paajanen T, Hänninen T, Tunnard C, Mecocci P, Sobow T, Tsolaki M, Vellas B, Lovestone S, Soininen H, Addneuromed Consortium.
    J Alzheimers Dis; 2010; 22(4):1089-97. PubMed ID: 20930314
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I, Illán-Gala I, Alcolea D, Sánchez-Saudinós MB, Salgado SA, Morenas-Rodríguez E, Subirana A, Videla L, Clarimón J, Carmona-Iragui M, Ribosa-Nogué R, Blesa R, Fortea J, Lleó A.
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [Abstract] [Full Text] [Related]

  • 4. CERAD-neuropsychological battery in screening mild Alzheimer's disease.
    Sotaniemi M, Pulliainen V, Hokkanen L, Pirttilä T, Hallikainen I, Soininen H, Hänninen T.
    Acta Neurol Scand; 2012 Jan; 125(1):16-23. PubMed ID: 21198445
    [Abstract] [Full Text] [Related]

  • 5. Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study.
    Hallikainen I, Hänninen T, Fraunberg M, Hongisto K, Välimäki T, Hiltunen A, Karppi P, Sivenius J, Soininen H, Koivisto AM, ALSOVA study group.
    Int Psychogeriatr; 2013 Aug; 25(8):1335-44. PubMed ID: 23676340
    [Abstract] [Full Text] [Related]

  • 6. Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment: A 5-year follow-up study.
    Yoon JH, Kim M, Moon SY, Yong SW, Hong JM.
    J Neurol Sci; 2015 Aug 15; 355(1-2):174-9. PubMed ID: 26076880
    [Abstract] [Full Text] [Related]

  • 7. CERAD test performances in amnestic mild cognitive impairment and Alzheimer's disease.
    Karrasch M, Sinervä E, Grönholm P, Rinne J, Laine M.
    Acta Neurol Scand; 2005 Mar 15; 111(3):172-9. PubMed ID: 15691286
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer's disease affected by E280A mutation on presenilin-1 gene.
    Aguirre-Acevedo DC, Jaimes-Barragán F, Henao E, Tirado V, Muñoz C, Reiman EM, Tariot PN, Langbaum JB, Lopera F.
    Int Psychogeriatr; 2016 Mar 15; 28(3):503-10. PubMed ID: 26478578
    [Abstract] [Full Text] [Related]

  • 9. CERAD Neuropsychological Total Scores Reflect Cortical Thinning in Prodromal Alzheimer's Disease.
    Paajanen T, Hänninen T, Aitken A, Hallikainen M, Westman E, Wahlund LO, Sobow T, Mecocci P, Tsolaki M, Vellas B, Muehlboeck S, Spenger C, Lovestone S, Simmons A, Soininen H, AddNeuroMed Consortium.
    Dement Geriatr Cogn Dis Extra; 2013 Jan 15; 3(1):446-58. PubMed ID: 24516412
    [Abstract] [Full Text] [Related]

  • 10. Ecological assessment of mild cognitive impairment and Alzheimer disease using the Rivermead Behavioural Memory Test.
    Bolló-Gasol S, Piñol-Ripoll G, Cejudo-Bolivar JC, Llorente-Vizcaino A, Peraita-Adrados H.
    Neurologia; 2014 Jan 15; 29(6):339-45. PubMed ID: 24139389
    [Abstract] [Full Text] [Related]

  • 11. The CERAD neuropsychological assessment battery total score detects and predicts Alzheimer disease dementia with high diagnostic accuracy.
    Wolfsgruber S, Jessen F, Wiese B, Stein J, Bickel H, Mösch E, Weyerer S, Werle J, Pentzek M, Fuchs A, Köhler M, Bachmann C, Riedel-Heller SG, Scherer M, Maier W, Wagner M, AgeCoDe Study Group.
    Am J Geriatr Psychiatry; 2014 Oct 15; 22(10):1017-28. PubMed ID: 23759289
    [Abstract] [Full Text] [Related]

  • 12. A total score for the CERAD neuropsychological battery.
    Chandler MJ, Lacritz LH, Hynan LS, Barnard HD, Allen G, Deschner M, Weiner MF, Cullum CM.
    Neurology; 2005 Jul 12; 65(1):102-6. PubMed ID: 16009893
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of Mild Cognitive Impairment Using the Thai Version of the Consortium to Establish a Registry for Alzheimer's Disease Tests: A Multivariate and Machine Learning Study.
    Tunvirachaisakul C, Supasitthumrong T, Tangwongchai S, Hemrunroj S, Chuchuen P, Tawankanjanachot I, Likitchareon Y, Phanthumchinda K, Sriswasdi S, Maes M.
    Dement Geriatr Cogn Disord; 2018 Jul 12; 45(1-2):38-48. PubMed ID: 29617684
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic value of digital clock drawing test in comparison with CERAD neuropsychological battery total score for discrimination of patients in the early course of Alzheimer's disease from healthy individuals.
    Müller S, Herde L, Preische O, Zeller A, Heymann P, Robens S, Elbing U, Laske C.
    Sci Rep; 2019 Mar 05; 9(1):3543. PubMed ID: 30837580
    [Abstract] [Full Text] [Related]

  • 15. CERAD test performance and cognitive impairment in Parkinson's disease.
    Karrasch M, Laatu S, Martikainen K, Marttila R.
    Acta Neurol Scand; 2013 Dec 05; 128(6):409-13. PubMed ID: 23668316
    [Abstract] [Full Text] [Related]

  • 16. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in detection and characterization of mild cognitive impairment due to Alzheimer's disease.
    Karantzoulis S, Novitski J, Gold M, Randolph C.
    Arch Clin Neuropsychol; 2013 Dec 05; 28(8):837-44. PubMed ID: 23867976
    [Abstract] [Full Text] [Related]

  • 17. Impact of white matter lesions and cognitive deficits on conversion from mild cognitive impairment to Alzheimer's disease.
    Defrancesco M, Marksteiner J, Deisenhammer E, Kemmler G, Djurdjevic T, Schocke M.
    J Alzheimers Dis; 2013 Dec 05; 34(3):665-72. PubMed ID: 23254639
    [Abstract] [Full Text] [Related]

  • 18. Predictors of cognitive decline in Alzheimer's disease and mild cognitive impairment using the CAMCOG: a five-year follow-up.
    Conde-Sala JL, Garre-Olmo J, Vilalta-Franch J, Llinàs-Reglà J, Turró-Garriga O, Lozano-Gallego M, Hernández-Ferrándiz M, Pericot-Nierga I, López-Pousa S.
    Int Psychogeriatr; 2012 Jun 05; 24(6):948-58. PubMed ID: 22278151
    [Abstract] [Full Text] [Related]

  • 19. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
    Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F, Popp J, Maier W, Hüll M, Frölich L, Hampel H, Perneczky R, Peters O, Jahn H, Luckhaus C, Gertz HJ, Schröder J, Pantel J, Lewczuk P, Kornhuber J, Wiltfang J.
    Neurology; 2012 Feb 07; 78(6):379-86. PubMed ID: 22238414
    [Abstract] [Full Text] [Related]

  • 20. Memory performance on the story recall test and prediction of cognitive dysfunction progression in mild cognitive impairment and Alzheimer's dementia.
    Park JH, Park H, Sohn SW, Kim S, Park KW.
    Geriatr Gerontol Int; 2017 Oct 07; 17(10):1603-1609. PubMed ID: 27910252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.